IP Verse

Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist - EP3889181

The patent EP3889181 was granted to Regeneron Pharmaceuticals on Apr 24, 2024. The application was originally filed on Sep 4, 2013 under application number EP21167811A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3889181

REGENERON PHARMACEUTICALS
Application Number
EP21167811A
Filing Date
Sep 4, 2013
Status
Granted And Under Opposition
Mar 22, 2024
Grant Date
Apr 24, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTJan 24, 2025BOULT WADE TENNANTADMISSIBLE
BRAND MURRAY FULLERJan 24, 2025BRAND MURRAY FULLERADMISSIBLE
DEHMEL & BETTENHAUSEN PATENTANWALTE PARTMBBJan 24, 2025RUCKERLADMISSIBLE
HAMPTON KNOWLESJan 24, 2025D YOUNGADMISSIBLE
LUIGIJan 24, 2025TER MEER STEINMEISTER & PARTNERADMISSIBLE
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBJan 24, 2025-ADMISSIBLE
SECERNAJan 23, 2025SECERNAADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2012097565
DESCRIPTIONUS6596541
DESCRIPTIONUS6927044
DESCRIPTIONUS7531637
DESCRIPTIONUS7582298
DESCRIPTIONUS7608693
OPPOSITIONEP3889181
OPPOSITIONUS2009074793
OPPOSITIONUS2012052072
OPPOSITIONWO2010053751
OPPOSITIONWO2012047954
OPPOSITIONWO2014039461
OPPOSITIONWO2022076289
SEARCHWO2010053751

Non-Patent Literature (NPL) Citations (103) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AI-LAZIKANI et al., J. Mol. Biol., (19970000), vol. 273, pages 927 - 948
DESCRIPTION- ANGAL et al., Molecular Immunology, (19930000), vol. 30, page 105
DESCRIPTION- CAGGANA et al., Genet. Med., (19990000), vol. 1, pages 267 - 271
DESCRIPTION- "Consensus Report of the European Task Force on Atopic Dermatitis", Dermatology (Basel), (19930000), vol. 186, no. 1, pages 23 - 31
DESCRIPTION- ELMANHYNAN, Brit. J. Dermatol., (20100000), vol. 162, pages 587 - 593
DESCRIPTION- GOODSON, Medical Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138
DESCRIPTION- HANIFIN et al., Exp. Dermatol., (20010000), vol. 10, pages 11 - 18
DESCRIPTION- HANIFIN et al., Exp. Dermetol, (20010000), vol. 10, pages 11 - 18
DESCRIPTION- HIJNEN et al., J. Allergy Clin. Immunol., (20040000), vol. 113, pages 334 - 340
DESCRIPTION- KOU et al., Arch. Dermatol. Res., (20120000), vol. 304, pages 305 - 312
DESCRIPTION- LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
DESCRIPTION- MARTIN et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, pages 9268 - 9272
DESCRIPTION- MASUOKA et al., J Clin Invest., (20120000), vol. 122, no. 7, pages 2590 - 2600
DESCRIPTION- MERRETT et al., Allergy, (19870000), vol. 17, pages 409 - 416
DESCRIPTION- MORDENTI et al., Pharmaceut. Res., (19910000), vol. 8, page 1351
DESCRIPTION- POWELL et al., "Compendium of excipients for parenteral formulations", J Pharm Sci Technol, (19980000), vol. 52, pages 238 - 311, XP009119027
DESCRIPTION- TAYLOR et al., Nucl. Acids Res., (19920000), vol. 20, pages 6287 - 6295
DESCRIPTION- TINTLE et al., J. Allergy Clin. Immunol., (20110000), vol. 128, pages 583 - 593
DESCRIPTION- WEIHRAUCH et al., Cancer Res., (20050000), vol. 65, page 13
DESCRIPTION- WU et al., J. Biol. Chem., (19870000), vol. 262, pages 4429 - 4432
EXAMINATION- VAN ASSCHE G ET AL, "Management of loss of response to anti-TNF drugs: Change the dose or change the drug?", JOURNAL OF CROHN'S AND COLITIS, ELSEVIER BV, NL, vol. 2, no. 4, doi:10.1016/J.CROHNS.2008.05.011, ISSN 1873-9946, (20081201), pages 348 - 351, (20080828), XP025692421
EXAMINATION- FOROOGHIAN FARZIN ET AL, "TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION", RETINA, US, vol. 29, no. 6, doi:10.1097/IAE.0b013e3181a2c1c3, ISSN 0275-004X, (20090601), pages 723 - 731, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770842/pdf/nihms-139616.pdf, XP093049977
EXAMINATION- GASPERINI JULIE L ET AL, "Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation", BRITISH JOURNAL OF OPHTHALMOLOGY, GB, (20110726), vol. 96, no. 1, doi:10.1136/bjo.2011.204685, ISSN 0007-1161, pages 14 - 20, XP093049978
OPPOSITION- Anonymous, "Dupilumab - ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS", EMEA, (20220901), XP093231635
OPPOSITION- Anonymous, "Dupilumab / Dupixent - Clinical Review", CENTER FOR DRUG EVALUATION AND RESEARCH, APPLICATION NUMBER: 761055Orig1s000, (20170315), CENTER FOR DRUG EVALUATION AND RESEARCH, APPLICATION NUMBER: 761055Orig1s000 , URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761055Orig1s000MedR.pdf, XP093257072
OPPOSITION- Anonymous, "DUPIXENT® (dupilumab) injection, for subcutaneous use - Highlights of prescribing information", FDA, (20220501), XP093257079
OPPOSITION- Anonymous, "ICH Topic E4 Dose Response Information to Support Drug Registration - NOTE FOR GUIDANCE ON DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION (CPMP/ICH/378/95) ", European Medicines Agency; CPMP/ICH/378/95, (19941101), European Medicines Agency; CPMP/ICH/378/95, (20240412), XP093150955
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN), List 108", WHO Drug Information, (20120101), vol. 26, no. 4, pages 401 - 471, XP055932074
OPPOSITION- Anonymous, "NCT01548404 Study of REGN668 in Adult Patients With Intrinsic Moderate-toSevere Atopic Dermatitis", ClinicalTrials.gov, (20120307), pages 1 - 7, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/history/NCT01548404?A=1&B=1&C=merged, (20190308), XP055566321
OPPOSITION- Anonymous, "REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL AND OPERATING RESULTS", R, egeneron, (20120213), R, (20220720), XP055944380
OPPOSITION- Antoniu S A, "Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, US , (20101101), vol. 11, no. 11, ISSN 1472-4472, pages 1286 - 1294, XP009160470
OPPOSITION- British National Formulary BNF 60, Royal Pharmaceutical Society, (20100900), page 418, 639, 640, 642
OPPOSITION- Charles Bankhead, "IL-4 Antibody Tames Atopic Dermatitis", Medpage Today, (20130303), pages 1 - 3, Medpage Today, URL: https://www.medpagetodaY.com/meetingcoverage/aad/37636, (20190308), XP055566311
OPPOSITION- D18 - Copies of four posters presented by Regeneron at the“International Investigative Dermatology” conference in Edinburgh in May 2013
OPPOSITION- D19 - Abstracts associated with posters presented at the“International Investigative Dermatology” conference in Edinburgh in May 2013. Journal of Investigative Dermatology (2013), Volume 1338 -11 May 2013
OPPOSITION- D30 - Filing Receipts of all US priority applications detailing named applicants
OPPOSITION- D31 - USPTO Pair recordal of assignments of all US priority applications from inventor/applicants to Regeneron, and Sanofi
OPPOSITION- D32 - Assignment to Regeneron- reel/frame 030844/0484
OPPOSITION- D33 - Assignment to Sanofi- reel/frame 030931/0570
OPPOSITION- D34 - Assignment to Sanofi Biotech- reel/frame 037055/0414
OPPOSITION- D43 - Applicant’s letter dated9 December 2011 from EP09744292.5
OPPOSITION- D49 - Form PCT/IB/306 dated 12 November 2014
OPPOSITION- D51 - Amended claims filed 26 July 2012 in US application 13/287,151
OPPOSITION- D59 - Patentee’s letter of5 May 2023 from examination
OPPOSITION- D60 - Note of telephone consultation with the examiner- 31 October 2023
OPPOSITION- D64 - Patentee’s letter of 25 March 2022 from examination
OPPOSITION- D65 - Patentee’s letter of 24 October 2023 from examination
OPPOSITION- D70 - submission of PP dated2 January 2023, from Oppo against EP3107575B1
OPPOSITION- D71 - Reasons dated7 March 2023, from Oppo against EP3107575B1
OPPOSITION- D76 - Office Action dated 31 October 2023
OPPOSITION- D J Birkett, "PHARMACOKINETICS MADE EASY 11 DESIGNING DOSE REGIMENS. ", (19960101), (20140827), XP055136785
OPPOSITION- Gibaldi Milo, "Biopharmaceutics and Clinical Pharmacokinetics (passage)", Biopharmaceutics and Clinical Pharmacokinetics, 4th ed., (19910101), pages 12 - 13, XP055945117
OPPOSITION- Groves R W, D Wilbraham, R Fuller, M Longphre , "Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema", Journal of Investigative Dermatology, (20070101), vol. 127, no. Abstract 320, page S54, XP093257082
OPPOSITION- Kostic, A. ; Zhang, W. ; Dore, A. ; Coopey, B. ; MacDonald, D. ; Fury, W. ; Lin, C. ; Hamilton, J. ; Classon, B. ; Papadopoulos, N.J. ; Murphy, A., "A Fully Human IL4R@? Antibody for Inhibition of IL-4/IL-13-driven Th2 Responses in Allergic Disease", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100101), vol. 135, ISSN 1521-6616, pages S105 - S106, XP027049116
OPPOSITION- Marlene Modi, "Dose-Finding Studies in Phase 1 and Estimation of Maximally Tolerated Dose", Dose Finding in Drug Development, Springer, (20060101), pages 30 - 48, ISBN 978-0-387-29074-4, XP009559022
OPPOSITION- Mould Diane R; Sweeney Kevin R D, "The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, GB , (20070101), vol. 10, no. 1, ISSN 1367-6733, pages 84 - 96, XP009097022
OPPOSITION- Nathanael L. Dirks & Bernd Meibohm, "Population Pharmacokinetics of Therapeutic Monoclonal Antibodies", CLINICAL PHARMACOKINETICS., ADIS INTERNATIONAL LTD., AUCKLAND, NZ, NZ , (20100101), vol. 49, no. 10, ISSN 0312-5963, pages 633 - 659, XP009558689
OPPOSITION- Proudfoot Stuart, Collet John, "Chapter 19 Dosage regimens", Aulton’s Pharmaceutics: The Science of Dosage Form Design. 2nd Ed., Churchill Livingstone , (20010101), pages 275 - 288, XP093198012
OPPOSITION- Regeneron Pharmaceuticals, "Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis - NCT01385657", Clinical Trials, Clinicaltrials.gov, (20120410), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01385657?term=NCT01385657&rank=1&tab=history&a=3#version-content-panel, XP093258214
OPPOSITION- Regeneron Pharmaceuticals, "Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis - NCT01385657", Clinical Trials, Clinicaltrials.gov, (20200224), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01385657?term=NCT01385657&rank=1&tab=history&a=5#version-content-panel, XP093258218
OPPOSITION- Regeneron Pharmaceuticals, "Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis - NCT01859988", Clinical Trials, Clinicaltrials.gov, (20130521), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01859988?term=NCT01859988&rank=1&tab=history&a=1#version-content-panel, XP093258224
OPPOSITION- Regeneron Pharmaceuticals, "Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis - NCT01548404", Clinical Trials, ClinicalTrials.gov, (20120419), pages 1 - 10, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01548404?term=NCT01548404&rank=1&tab=history&a=2#version-content-panel, XP093258138
OPPOSITION- Regeneron Pharmaceuticals, "Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis - NCT01548404", Clinical Trials; version 7, Clinicaltrials.gov, (20171113), Clinical Trials; version 7, URL: https://clinicaltrials.gov/study/NCT01548404?term=NCT01548404&rank=1&tab=history&a=7#version-content-panel, XP093258188
OPPOSITION- Regeneron Pharmaceuticals, "Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) - NCT01639040", Clinical Trials, Cliniclatrials.gov, (20120711), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01639040?term=NCT01639040&rank=1&tab=history&a=1#version-content-panel, XP093258220
OPPOSITION- "Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis", 71st Annual Meeting of the American Academy of Dermatology, (20130302), pages 1 - 3, XP007922251
OPPOSITION- Sanofi, "An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma - NCT01854047", Clinical Trials, Clinicaltrials.gov, (20130510), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01854047?term=NCT01854047&rank=1&tab=history&a=1#version-content-panel, XP093258227
OPPOSITION- Lin Y T, Wang C T, Chiang B L, "Role of bacterial pathogens in atopic dermatitis.", CLINICAL REVIEWS IN ALLERGY AND IMMUNOLOGY, HUMANA PRESS, TOTOWA, NJ, US, US , (20071201), vol. 33, no. 3, doi:10.1007/s12016-007-0044-5, ISSN 1080-0549, pages 167 - 177, XP002739302
OPPOSITION- Schumacher Beate, "Neuer Antikörper bessert eosinophiles Asthma", Allergo Journal, (20130901), vol. 22, doi:10.1007/s15007-013-0348-0, page 361, XP093257095
OPPOSITION- Beck Lisa A., Deleuran Mette, Bissonnette Robert, De Bruin-Weller Marjolein, Galus Ryszard, Nakahara Takeshi, Seo Seong Jun, Khokhar Faisal A., Vakil Jignesh, Xiao Jing, Marco Ainara Rodriguez, Levit Noah A., O’malley John T., Shabbir Arsalan, "Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis", American Journal of Clinical Dermatology, Springer Nature, (20220501), vol. 23, no. 3, doi:10.1007/s40257-022-00685-0, ISSN 1175-0561, pages 393 - 408, XP093257103
OPPOSITION- Joost, Th.v. ; Kozel, M.M.A. ; Tank, B. ; Troost, R. ; Prens, E.P., "Cyclosporine in atopic dermatitis:Modulation in the expression of immunologic markers in lesional skin", Journal of the American Academy of Dermatology, Mosby, Inc, US, US , (19921201), vol. 27, no. 6, doi:10.1016/0190-9622(92)70288-Q, ISSN 0190-9622, pages 922 - 928, XP023982703
OPPOSITION- Thomas Werfel , Alexander Kapp, "Chapter 13: D54 - Atopic dermatitis and allergic contact dermatitis", Allergy, Elsevier , (20120101), pages 263 - 286, doi:10.1016/B978-0-7234-3658-4.00017-2, ISBN 978-0-7234-3658-4, XP009559975
OPPOSITION- Van Assche, G. ; Vermeire, S. ; Rutgeerts, P., "Management of loss of response to anti-TNF drugs: Change the dose or change the drug?", Journal of Crohn's and Colitis, Elsevier BV, NL, NL , (20081201), vol. 2, no. 4, doi:10.1016/j.crohns.2008.05.011, ISSN 1873-9946, pages 348 - 351, XP025692421
OPPOSITION- Tran-Hoai Nguyen, Jeffrey R Stokes And Thomas B Casale, "Future Forms of Immunotherapy and Immunomodulators in Allergic Disease", Immunol Allergy Clin N Am, (20110101), doi:10.1016/j.iac.2011.02.003, pages 343 - 365, XP055566273
OPPOSITION- Radin Allen, Haobo Ren, Pamela Papino-Wood, Usman Chaudry, Jennifer D. Hamilton, "558 First-in-Human Study of REGN668/SAR231893 (IL-4Ra mAb): Safety, Tolerability and Biomarker Results of a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers", J ALLERGY CLIN IMMUNOL, (20130201), vol. 131, no. 2, doi:10.1016/j.jaci.2012.12.1224, page AB158, XP093257087
OPPOSITION- Hwang, W.Y.K. Foote, J., "Immunogenicity of engineered antibodies", Methods, Academic Press, NL, NL , (20050501), vol. 36, no. 1, doi:10.1016/j.ymeth.2005.01.001, ISSN 1046-2023, pages 3 - 10, XP004852548
OPPOSITION- W Wang, Eq Wang, Jp Balthasar, "Monoclonal Antibody Pharmacokinetics and Pharmacodynamics", Clinical Pharmacology & Therapeutics, (20081101), vol. 84, no. 5, doi:10.1038/clpt.2008.170, ISSN 00099236, pages 548 - 558, XP055152777
OPPOSITION- Eisenstein M, "Something new under the skin", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20110101), vol. 29, no. 2, doi:10.1038/nbt.1768, ISSN 1087-0156, pages 107 - 109, XP009152843
OPPOSITION- Wenzel Sally; Ford Linda; Pearlman David; Spector Sheldon; Sher Lawrence; Skobieranda Franck; Wang Lin; Kirkesseli Stephane; Rocklin Ross; Bock Brian; Hamilton Jennifer; Ming Jeffrey E; Radin Allen; Stahl Neil; Yancopoulos George D; Graham Neil; Pirozzi Gianluca, "Dupilumab in Persistent Asthma with Elevated Eosinophil Levels", The New England journal of medicine, Massachusetts Medical Society, US, US , (20130627), vol. 368, no. 26, doi:10.1056/NEJMoa1304048, ISSN 0028-4793, pages 2455 - 2466, XP008165248
OPPOSITION- John-Paul Silva, Olivia Vetterlein, Joby Jose, Shirley Peters, Hishani Kirby, "The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20150227), vol. 290, no. 9, doi:10.1074/jbc.M114.600973, ISSN 0021-9258, pages 5462 - 5469, XP055299482
OPPOSITION- Christophe Dumet, Jérémy Pottier, Valérie Gouilleux-Gruart, Hervé Watier, "Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development", mAbs, Landes Bioscience, US, US , (20191117), vol. 11, no. 8, doi:10.1080/19420862.2019.1664365, ISSN 1942-0862, pages 1341 - 1350, XP055732501
OPPOSITION- Handlogten Michael W., Peng Li, Christian Elizabeth A., Xu Weichen, Lin Shihua, Venkat Raghavan, Dall’acqua William, Ahuja Sanjeev, "Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region", mAbs, Landes Bioscience, US, US , (20200101), vol. 12, no. 1, doi:10.1080/19420862.2020.1779974, ISSN 1942-0862, page 1779974, XP055869374
OPPOSITION- Forooghian Farzin, Cukras Catherine, Meyerle Catherine B., Chew Emily Y., Wong Wai T., "TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION", Retina, Lippincott, Williams & Wilkins, US, US , (20090601), vol. 29, no. 6, doi:10.1097/IAE.0b013e3181a2c1c3, ISSN 0275-004X, pages 723 - 731, XP093049977
OPPOSITION- T. Morioka; K. Yamanaka; H. Mori; Y. Omoto; K. Tokime; M. Kakeda; I. Kurokawa; E.C. Gabazza; A. Tsubura; Y. Yasutomi; H. Mizutani, "IL‐4/IL‐13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis", British journal of dermatology (1951), Wiley, (20090313), vol. 160, no. 6, doi:10.1111/j.1365-2133.2009.09069.x, ISSN 0007-0963, pages 1172 - 1179, XP071109316
OPPOSITION- Ring J., Alomar A., Bieber T., Deleuran M., Fink‐wagner A., Gelmetti C., Gieler U., Lipozencic J., Luger T., Oranje A.P., Schäfer T., Schwennesen T., Seidenari S., Simon D., Ständer S., Stingl G., Szalai S., Szepietowski J.C., Taïeb A., Werfel T., Wollenberg A., Darsow U., "Guidelines for treatment of atopic eczema (atopic dermatitis) Part I", JEADV , The Journal of the European Academy of Dermatology and Venereology, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, NL , (20120101), vol. 26, no. 8, doi:10.1111/j.1468-3083.2012.04635.x, ISSN 0926-9959, pages 1045 - 1060, XP093235834
OPPOSITION- Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C., Gieler U., Lipozencic J., Luger T., Oranje A.P., Schäfer T., Schwennesen T., Seidenari S., Simon D., Ständer S., Stingl G., Szalai S., Szepietowski J.C., Taïeb A., Werfel T., Wollenberg A., Darsow U., "Guidelines for treatment of atopic eczema (atopic dermatitis) Part II : Guidelines for treatment of atopic eczema", JEADV , The Journal of the European Academy of Dermatology and Venereology, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, NL , (20120901), vol. 26, no. 9, doi:10.1111/j.1468-3083.2012.04636.x, ISSN 0926-9959, pages 1176 - 1193, XP055780332
OPPOSITION- Tran-Hoai T. Nguyen, Thomas B. Casale, "Immune modulation for treatment of allergic disease", Immunological Reviews, (20110720), vol. 242, no. 1, doi:10.1111/j.1600-065X.2011.01034.x, ISSN 01052896, pages 258 - 271, XP055143463
OPPOSITION- Gasperini et al., "Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation", British Journal of Ophthalmology, (20110726), vol. 96, no. 1, doi:10.1136/bjo.2011.204685, pages 14 - 20, XP093049978
OPPOSITION- Panaccione Remo, Ghosh Subrata, "Review: Optimal use of biologics in the management of Crohn’s disease", Therapeutic Advances in Gastroenterology, SAGE, (20100501), vol. 3, no. 3, doi:10.1177/1756283X09357579, ISSN 1756-2848, pages 179 - 189, XP055928707
OPPOSITION- A. Garriga, "Annual Meeting of the American Academy of Dermatology (AAD), Miami Beach, Florida - March 1-5, 2013", Drugs of the Future, Prous Science, ES, ES , (20130301), vol. 38, no. 4, doi:10.1358/dof.2013.38.4.1965490, ISSN 0377-8282, pages 275 - 279, XP009559964
OPPOSITION- Ong Peck Y, "Editorial update on emerging treatments of atopic dermatitis", Expert opinion on emerging drugs England, Informa Healthcare, UK, UK , (20120601), vol. 17, no. 2, doi:10.1517/14728214.2012.668884, ISSN 1744-7623, pages 129 - 133, XP009171977
OPPOSITION- Diane R. Mould, Bruce Green, "Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies", BIODRUGS, Adis International Ltd., NZ, NZ , (20100201), vol. 24, no. 1, doi:10.2165/11530560-000000000-00000, ISSN 1173-8804, pages 23 - 39, XP009514743
SEARCH- A GARRIGA, "71st ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY (AAD)", DRUGS OF THE FUTURE, (20130301), pages 275 - 279, XP055566346 [IP] 1-11 * page 276, column l, paragraph l - column r, paragraph 1 *
SEARCH- Charles Bankhead, "IL-4 Antibody Tames Atopic Dermatitis", Medpage Today, (20130303), pages 1 - 3, URL: https://www.medpagetodaY.com/meetingcoverage/aad/37636, (20190308), XP055566311 [IP] 1-11 * the whole document *
SEARCH- GIL YOSIPOVITCH ET AL, "IL-4Ralpha mAb dupilumab (REGN668/SAR231893) for the Treatment of Severe Atopic Dermatitis Itch, abstract 1050", INTERNATIONAL INVESTIGATIVE DERMATOLOGY, Edinburgh, (20130508), XP055566307 [IP] 1-11 * the whole document *
SEARCH- JENNIFER D HAMILTON ET AL, "Biomarkers elevated in atopic dermatitis (AD) are reduced by therapeutic blockade of IL-4 receptor a (IL-4ralpha) signaling with dupilumab in patients with moderate-to-severe AD. abstract 1042", INTERNATIONAL INVESTIGATIVE DERMATOLOGY, Edinburgh, (20130508), XP055566280 [IP] 1-11 * the whole document *
SEARCH- J HAMILTON ET AL, "Blocking IL-4Ralpha with dupilumab (REGN668/SAR231893) rapidly suppresses major pathogenic pathways in severe atopic dermatitis, abstract 1048", INTERNATIONAL INVESTIGATIVE DERMATOLOGY, Edinburgh, (20130508), XP055566293 [IP] 1-11 * the whole document *
SEARCH- L BECK ET AL, "Systemic treatment of adult patients with severe atopic dermatitis with the IL-4Ralpha mAb, dupilumab, results in rapid and sustained improvements in disease signs and symptoms, abstarct 1049", INTERNATIONAL INVESTIGATIVE DERMATOLOGY, Edinburgh, (20130508), XP055566302 [IP] 1-11 * the whole document *
SEARCH- N N, "Abstracts "Human Clinical Research and Therapeutics"", JOURNAL OF INVESTIGATIVE DERMATOLOGY, (20130501), vol. 133, no. suppl. 1, XP055828590 [IP] 1-11 * Abstracts 1042 and 1048-1050 *
SEARCH- TARUNDEEP KAKKAR ET AL, "Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, (20110521), vol. 28, no. 10, doi:10.1007/S11095-011-0481-Y, ISSN 1573-904X, pages 2530 - 2542, XP019950375 [A] 1-11 * the whole document *
SEARCH- JUDITH HONG ET AL, "Management of Itch in Atopic Dermatitis", SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, vol. 30, no. 2, doi:10.1016/J.SDER.2011.05.002, ISSN 1085-5629, (20110514), pages 71 - 86, (20110514), XP028240445 [A] 1-11 * the whole document *
SEARCH- BECK LISA A ET AL, "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, (20140710), vol. 371, no. 2, doi:10.1056/NEJMOA1314768, ISSN 1533-4406, pages 130 - 139, XP009180485 [T] * the whole document *
SEARCH- D M PATON, "Dupilumab: human monoclonal antibody against IL-4Ralpha for moderate to severe atopic dermatitis", DRUGS TODAY, (20170901), vol. 53, no. 9, doi:10.1358/dot.2017.53.9.2693150, pages 477 - 487, XP055465888 [T] * the whole document *
SEARCH- ONG PECK Y, "Editorial update on emerging treatments of atopic dermatitis", EXPERT OPINION ON EMERGING DRUGS ENGLAND, INFORMA HEALTHCARE, UK, (20120601), vol. 17, no. 2, doi:10.1517/14728214.2012.668884, ISSN 1744-7623, pages 129 - 133, XP009171977 [A] 1-11 * page 129, paragraph l * * table 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents